Sign up
Log in
Reported Sunday, Bristol Myers Squibb's Phase 3 SCOUT-HCM Trial Of Camzyos Meets Primary Endpoint In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Share
Listen to the news
  • Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28
  • Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents
  • Safety profile of Camzyos in adolescents was similar to established profile in adults, with no new safety signals and no patients experiencing left ventricular ejection fraction (LVEF) of <50%
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved